



ASX ANNOUNCEMENT

24 June 2025

RESULTS OF ENTITLEMENT OFFER

Cardiex Limited (ASX: CDX) (“**Cardiex**” or “the **Company**”) is pleased to advise the results of its fully underwritten, non-renounceable pro-rata entitlement offer (“**Entitlement Offer**”) to raise approximately \$4.1 million. Combined with the completion of the Institutional Placement announced on 30 May 2025, tranche 1 of which has already completed, the Company has now received funds and commitments for a total of \$6.5 million (before costs).

The Entitlement Offer was well supported by eligible shareholders, who applied for approximately 49,389,383 new shares, along with an additional 1,717,515 new shares under the Top-Up Offer, representing a total take-up of approximately 50.3% of the Entitlement Offer. The balance of the Entitlement Offer was allocated to the underwriter and sub-underwriters in accordance with the underwriting arrangements.

C2 Ventures (a company jointly owned by Directors Niall Cairns and Craig Cooper), as well as with Directors and other entities associated with Directors of the Company took up their entitlements totaling 33,753,338 new shares, representing a value of \$1,350,133.08.

The Entitlement Offer was fully underwritten by Blackpeak Capital Pty Ltd, which entered into sub-underwriting agreements with a number of parties including C2 Ventures and certain of its associates. These sub-underwriters took up their full entitlements, totaling 50,409,547 new shares, representing a value of \$2,016,381.88.

New Shares under the Entitlement Offer (including the underwritten shortfall shares) will be issued on Friday, 27 June 2025 and will rank equally with existing ordinary shares on issue. 18,409,580 shares to be issued to C2V as a result of C2V’s participation in the tranche 2 placement is subject to shareholder approval pursuant to ASX Listing Rule 10.11 and will be issued at a later date.

Blackpeak Capital, Stralis Capital Partners Pty Ltd, and Taylor Collison were joint-lead managers of the Entitlement Offer.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About CARDIEX

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").